News

NEWS
Press-Release
October 1, 2018
InSysBio Announces Continuation of Collaboration with MedImmune for Quantitative Systems Pharmacology Modeling in Systemic Lupus Erythematosus
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced today an extension of a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for QSP modeling in systemic lupus erythematosus (SLE). The goal is to support the clinical development of anifrolumab, an investigational monoclonal antibody against the type I interferon receptor, by modeling the contributions of key cell types involved in the pathophysiology of lupus that are associated with the type I interferon dysregulation commonly seen with the disease.
LEARN MORE
NEWS
Software
September 26, 2018
InSysBio launches Immune Response Template online
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced the launch of Immune Response Template (IRT) online. IRT is a QSP platform of human immune system and a tool for development of custom QSP models related to immune response.
LEARN MORE
NEWS
Press-Release
September 11, 2018
InSysBio launches Alzheimer’s Disease Modeling Consortium
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced the launch of Alzheimer’s Disease (AD) Modeling Consortium. The aim of the consortium is the support of drug development in AD by consolidation of efforts of teams from various pharmaceutical companies in framework of development and application of AD QSP platform.
LEARN MORE
NEWS
Press-Release
August 15, 2018
InSysBio creates a legal entity in UK
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced the registration of legal entity in UK. InSysBio UK (INSYSBIO UK LIMITED) is located in Edinburgh.
LEARN MORE
NEWS
Press-Release
June 13, 2018
InSysBio Announces Collaboration on Quantitative System Pharmacology Modeling of Chronic Obstructive Pulmonary Disease
InSysBio LLC (www.insysbio.com), a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a collaboration with GSK, one of the world's leading research-based pharmaceutical and healthcare companies, for development of QSP platform of Chronic Obstructive Pulmonary Disease (COPD).
LEARN MORE
NEWS
Press-Release
April 26, 2018
InSysBio, LLC Announces Extension of Collaboration with GSK on Quantitative Systems Pharmacology Modeling in Asthma
InSysBio LLC (www.insysbio.com) – pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development – announced today further collaboration with GSK - one of the world's leading research-based pharmaceutical and healthcare companies - to expand the previously developed QSP model of asthma.
LEARN MORE
June 2022
MoTuWeThFrSaSu
  
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
   
Upcoming Events
Tags